{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T21:45:44Z","timestamp":1786139144659,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clinme.2026.100629","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:41:46Z","timestamp":1784590906000},"page":"100629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic dysfunction-associated steatotic liver disease (MASLD) is under-recognised: Should hepatic elastography be integrated into early risk stratification for people with type 2 diabetes?"],"prefix":"10.1016","volume":"26","author":[{"given":"Aftab","family":"Ala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ponnusamy","family":"Saravanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10541","key":"10.1016\/j.clinme.2026.100629_bib1","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(26)00138-8","article-title":"Implementing sustainable liver health in Europe: a second EASL-Lancet Commission","volume":"407","author":"Karlsen","year":"2026","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clinme.2026.100629_bib2","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.metabol.2016.01.008","article-title":"Similarities and differences between pediatric and adult nonalcoholic fatty liver disease","volume":"65","author":"Crespo","year":"2016","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.clinme.2026.100629_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S2468-1253(26)00011-7","article-title":"Global burden of metabolic dysfunction-associated steatotic liver disease, 1990\u22122023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023","volume":"11","author":"GBD 2023 MASLD Collaborators","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100629_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/HEP.0000000000001564","article-title":"Global performance of non-invasive tests in MASLD: insights from the G-MASLD study","volume":"84","author":"Younossi","year":"2026","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.clinme.2026.100629_bib5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jhep.2024.06.018","article-title":"Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection","volume":"81","author":"Fuster-Anglada","year":"2024","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.clinme.2026.100629_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cgh.2023.09.018","article-title":"Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies","volume":"22","author":"Chan","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.clinme.2026.100629_bib7","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.clnu.2024.04.034","article-title":"Risk factors for decreased bone mineral density in patients with metabolic dysfunction-associated steatotic liver disease: a cross-sectional study at a health examination center","volume":"43","author":"Yokoyama","year":"2024","journal-title":"Clin Nutr"},{"issue":"1","key":"10.1016\/j.clinme.2026.100629_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3350\/cmh.2024.0631","article-title":"Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations","volume":"31","author":"Danpanichkul","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10.1016\/j.clinme.2026.100629_bib9","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1210\/jc.2013-3253","article-title":"Association of adipose tissue and liver fibrosis with tissue stiffness in morbid obesity: links with diabetes and BMI loss after gastric bypass","volume":"99","author":"Abdennour","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.clinme.2026.100629_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17474124.2025.2607008","article-title":"Guideline comparison for fatty liver disease: European (EASL-EASD-EASO) and Asian (APASL) perspectives","volume":"20","author":"Abenavoli","year":"2026","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.clinme.2026.100629_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101709","article-title":"Management of patients with type 2 diabetes and MASLD: an overview and joint statement","volume":"51","author":"Chouik","year":"2025","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.clinme.2026.100629_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2026.100461","article-title":"Heterogeneous associations of regional adipose depots with liver fibrosis in U.S. adults","volume":"30","author":"Lai","year":"2026","journal-title":"Metabol Open"},{"issue":"4","key":"10.1016\/j.clinme.2026.100629_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinme.2026.100585","volume":"26","author":"Silva-Tinoco","year":"2026","journal-title":"Clin Med"},{"key":"10.1016\/j.clinme.2026.100629_bib14","article-title":"GLP\u22121 receptor agonist-SGLT\u22122 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes","author":"Mao","year":"2026","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.clinme.2026.100629_bib15","doi-asserted-by":"crossref","first-page":"e2542750","DOI":"10.1001\/jamanetworkopen.2025.42750","article-title":"Cost-effectiveness of MASH diagnosis and management approaches among those with type 2 diabetes","volume":"8","author":"Lazarus","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211826000783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211826000783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:53:10Z","timestamp":1786135990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211826000783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1470211826000783"],"URL":"https:\/\/doi.org\/10.1016\/j.clinme.2026.100629","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction-associated steatotic liver disease (MASLD) is under-recognised: Should hepatic elastography be integrated into early risk stratification for people with type 2 diabetes?","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2026.100629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2026.100585","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100629"}}